PATENT CLAIM ANALYSIS

Application Number: 16212787
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-03
Patent Classification: ["424", "134100"]

Abstract:
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Claim (Index 11):
The method of  claim 1 , wherein the cancer is lung cancer.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 98.0
- Lexical Diversity: 1.61972
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16212783', '16054561', '15978700', '15082876', '15799495']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8481137207378188
- 35 USC 102 Novelty (BERT): 0.5906832096703073
- Combined Prediction Score: 0.8223706696310676
- Mean Citation Score: 637.902914
- Max Citation Score: 641.0009
- Similarity Product: 411.6713287460448

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test